PRTK - Paratek Pharmaceuticals up 20% on takeout speculation - report
2023-03-21 13:17:27 ET
- Paratek Pharmaceuticals ( NASDAQ: PRTK ) is up 20% in Tuesday afternoon trading amid a report that the biopharma is a takeout target.
- Betaville Intelligence is reporting that those familiar with the situation say a private equity firm is the leading suitor.
- Paratek's ( PRTK ) marketed products include the antibiotics Nuzyra (omadacycline) and Seysara (sarecycline).
- Seeking Alpha's Quant Rating views Paratek ( PRTK ) as a hold.
For further details see:
Paratek Pharmaceuticals up 20% on takeout speculation - report